Solventum (SOLV): financials, SEC filings and peers
Solventum (SOLV) is a health care technology company in the Health Care sector of the S&P 500, headquartered in Saint Paul, Minnesota.
It was founded in 2023 and joined the S&P 500 on April 1, 2024.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Surgical & Medical Instruments & Apparatus”.
Solventum at a glance
- Revenue (12 months)
- $8.2B
- Revenue growth
- -2.8%
- Operating margin
- 5.6%
- Net income (12 months)
- $156M
- Free cash flow (12 months)
- $0
- Cash
- $451M
- Debt
- $5.1B
- Diluted EPS (12 months)
- $0.88
Twelve months to September 30, 2026, from the 10-Q filed November 5, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, Solventum reported revenue of $8.2 billion, down 2.8% from $8.4 billion a year earlier.
Its operating margin was 5.6%, down 20.5 percentage points from a year earlier: for every $100 of sales, about $6 was left as operating profit.
Net income was $156 million (1.9% of revenue), 89.8% lower than a year earlier.
Operating cash flow was $310 million and capital spending $310 million, leaving free cash flow of $0 (0.0% of revenue).
At the end of the period it held $451 million in cash and $5.1 billion in debt, a net debt position of $4.6 billion.
The diluted share count fell 2.6% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $8.1 billion in fiscal 2022 to $8.3 billion in fiscal 2025, about 0.8% a year.
- Revenue has grown for 3 fiscal years in a row.
- Operating margin widened from 20.8% to 26.2% over the same years.
- Free cash flow was negative in 1 of the last 4 fiscal years.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $8.1B | $8.2B | $8.3B | $8.3B |
| Revenue growth | — | 0.8% | 0.7% | 0.9% |
| Operating margin | 20.8% | 20.6% | 12.6% | 26.2% |
| Net income | $1.3B | $1.3B | $479M | $1.6B |
| Free cash flow | $1.4B | $1.6B | $805M | −$10M |
| Diluted EPS | $7.78 | $7.79 | $2.76 | $8.88 |
Fiscal years as reported in Solventum’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed November 5, 2026 — quarterly report
- 8-K filed November 5, 2026 — Earnings results
- 10-Q filed August 5, 2026 — quarterly report
- 8-K filed August 5, 2026 — Earnings results
- 8-K filed August 5, 2026 — Regulation FD disclosure; Other event
- 8-K filed July 20, 2026 — Executive or director change
- 8-K filed June 5, 2026 — Other event
- 8-K filed May 27, 2026 — Executive or director change
Companies like Solventum
Other S&P 500 companies in Health Care Technology:
More from Health Care
Questions about Solventum
Is Solventum's revenue growing?
No. Revenue for the twelve months to September 30, 2026 was $8.2 billion, down 2.8% from a year earlier, according to its SEC filings.
Is Solventum profitable?
Yes. It earned $156 million in net income over the twelve months to September 30, 2026, a net margin of 1.9%.
Does Solventum have more cash or more debt?
At September 30, 2026 it had $451 million in cash and $5.1 billion in debt, so more debt than cash.
When did Solventum last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on November 5, 2026.
Which companies are similar to Solventum?
In the S&P 500, Solventum is grouped in Health Care Technology within the Health Care sector. Veeva Systems (VEEV) are in the same group.
Understand the numbers
Source: Solventum’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.